Background: Lifetime risk for cardiovascular (CV) disease is high but predicting incident events on an individual level remains difficult. Single measurements of galectin-3, a marker of tissue fibrosis, predict mortality and new-onset heart failure (HF). Persistently elevated levels may indicate a clinically silent disease process.
The follow-up time of the present study ranged from the second follow-up visit to 31 December 2010 or the event if this occurred before this date. Subjects were censored on the dates of either moving away to an unknown location or last study visit, whichever occurred first. Changes in galectin-3 concentration were assessed by three different methods: (1) to assess the prognostic value of high galectin-3 levels over time, participants were categorised in two groups: patients with persistently elevated galectin-3 levels and patients with non-persistently elevated galectin-3 levels. We defined galectin-3 levels above the third quartile as elevated, so the category of persistently elevated galectin-3 level identifies patients with galectin-3 levels above the third quartile at baseline and above the third quartile at their follow-up visit (Q4-Q4), whereas the category of nonpersistently elevated galectin-3 levels identifies all other patients who are not in Q4-Q4. (2) To study the effect of changes in galectin-3, subjects were divided into four groups, based on changes in galectin-3 levels from baseline to follow-up across a threshold level. This level was calculated as the concentration of galectin-3 that yielded the highest Youden index (highest product of sensitivity and specificity) for experiencing new-onset HF, which were 12.2 ng/mL at baseline and 14.6 ng/mL at follow-up. (3) Furthermore, in an additional sensitivity analysis, we studied the prognostic value of absolute change in galectin-3 over time, which was also categorised in four equal quartiles. 
statistical analyses
Normally distributed variables are presented as means±SD. Non-normally distributed variables are expressed as medians (IQR) and were log-transformed before regression analyses. Clinical and biochemical characteristics were compared across two groups using two-sample t test for continuous, normally distributed variables, Wilcoxon ranksum test for continuous, non-normally distributed variables and χ 2 test for categorical variables. Baseline characteristics were also compared across four groups using analysis of variance, Kruskal-Wallis test and χ 2 test. To correct for years of sample storage, a linear correction coefficient for the follow-up galectin-3 measurements was applied, for each age category. The PREVEND trial was set up to overselect participants with increased urinary albumin excretion (UAE) (>10 mg/L). A design-based statistical weighting was used to adjust for this overselection, allowing conclusions to be made for the general population.
Time to event between different groups, based on galectin-3 levels over time, was compared using cumulative incidence curves and Wald χ 2 tests. To account for death as competing risk for other outcomes, subjects' follow-up time was censored at the time of death whenever death occurred before the onset of outcome. The association between serial galectin-3 with several end points was studied employing competing risk regression based on a proportional hazards model using HRs as measures of association, with 95% CIs based on robust standard error estimates. The model was adjusted for all baseline characteristics except for the covariates that showed collinearity (cholesterol, low-density lipoprotein, high-density lipoprotein, creatinine, cystatin-C).
The prognostic discrimination of a single determination of galectin-3 compared with serial measurements of galectin-3 was assessed by the Harrell's C index and 95% CIs were calculated using the method of Newson to compare the predictive power of survival models, as described previously. 22 We furthermore estimated the integrated discrimination improvement (IDI) and the category-free net reclassification improvement (NRI) for the addition of baseline or serial galectin-3 in fully adjusted models. p<0.05 (two-sided) was used as level of statistical significance. All analyses were performed using Stata/MP (V.14.0).
ResulTs study population and baseline characteristics
Baseline characteristics of 5958 subjects are presented in table 1 for subjects with persistently elevated (defined as galectin-3 levels in the fourth quartile at both time points) (Q4-Q4) and non-persistently elevated galectin-3 (not Q4-Q4). Characteristics of participants that were excluded in the present study are presented in supplementary table S1. Median (IQR) follow-up time of the present study was 8.3 (7.8-8.9 ) years from the first follow-up visit. The median galectin-3 level at baseline was 10.8 (9.0-13.0) and increased to 11.5 (9.0-14.4) after ~4 years of follow-up and was higher in female (baseline: 11.0 (9.1-13.3); follow-up: 11.7 (9.1-14.8)) compared with male subjects (10.6 (8.9-12.6); 11.3 (8.9-14.0); p<0.0001; figure 1 ). Subjects with persistently high galectin-3 levels (Q4-Q4) had an elevated CV risk: they were older, were more often female, were less likely to smoke, had more frequently diabetes mellitus type 2, a higher prevalence of myocardial infarction (MI), hypertension, hypercholesterolaemia and stroke, a higher blood pressure, a lower estimated glomerular filtration rate (eGFR) and had higher levels of cholesterol, triglycerides, glucose, creatinine, UAE, high-sensitivity C reactive protein, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and galectin-3 (table 1) . The aetiology of HF was similar to subjects with non-persistently elevated galectin-3 levels (see supplementary table S2 ). We also studied changes of galectin-3 over time using our defined optimised cut points at baseline (12.2 ng/mL) and at follow-up (14.6 ng/mL); baseline characteristics of these categories are presented in supplementary table S3. To further explore the effects of galectin-3 dynamics, we also show the absolute change in galectin-3, and was also categorised by quartiles of absolute change in galectin-3 (see supplementary table S4 ). Patients with the highest increase of galectin-3 over a 4-year time period were older, had more often hypertension and hypercholesterolaemia, lower eGFR, higher NT-proBNP and lower galectin-3 at baseline. Box-and-whisker plot showing the plasma galectin-3 levels (ng/mL) at baseline and at follow-up in male and female subjects. The boxplot represents median and IQR and whiskers represent the first and 99th percentile.
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Galectin-3 levels over time and event rate
All subjects were followed for a mean duration of 8 years after their first follow-up measurement. A total of 352 individuals died, with 86 due to CV causes. Furthermore, 188 subjects experienced new-onset HF (of which 73 subjects with HF with preserved ejection fraction (HFpEF) and 115 subjects with HF with reduced ejection fraction (HFrEF)), 537 a CV event and 225 participants experienced new-onset atrial fibrillation (AF). Baseline and follow-up galectin-3 levels were classified into quartiles. The association between serial galectin-3 levels and events is depicted in 4×4 heat plots of serial galectin-3 levels with its corresponding event rate (figure 2). Subjects with persistently high galectin-3 levels (fourth quartile at baseline and fourth quartile at follow-up) over time have the highest event rate for CV mortality, new-onset HF, all-cause mortality, new-onset AF and CV events (figure 2; see supplementary figure S1 and S2). To visualise and calculate the differences between the persistently elevated subjects in comparison to the pooled non-persistently elevated subjects, cumulative incidence curves were plotted, which showed that individuals with persistently elevated galectin-3 levels, compared with non-persistently elevated, demonstrate a higher CV mortality (Wald χ 2 test: p<0.0001), higher cumulative incidence of HF (p<0.0001) (figure 3) and also a higher all-cause mortality (p<0.0001), higher cumulative incidence of new-onset AF (p=0.005) and more CV events (p<0.0001) (see supplementary figure S3 ). We conducted secondary analysis using an optimised cut point creating four groups (low-low, low-high, high-low and high-high). Analysis of categorical change of galectin-3 over time showed the highest event rate in the 'high-high group' for all end points (figure 4; see supplementary figure S4 ). Furthermore, the association between absolute change of galectin-3 over time and outcome was studied to determine whether the level of change in galectin-3 was important. Cumulative incidence curves, by quartile of absolute change in galectin-3, showed that the absolute change in galectin-3 was associated with increased CV mortality (Wald χ 2 test: p=0.02), all-cause mortality (p=0. 
independent predictive value of serial galectin-3 levels
The independent predictive value of serial galectin-3 levels over a ∼ 4-year time period was assessed with competing-risks regression models, and included adjustment for all baseline characteristics (table 2) . In a univariable analysis, persistently elevated galectin-3 levels were associated with CV mortality, new-onset HF, all-cause mortality, new-onset AF and CV event (table 2, see supplementary table S5 ), compared with subjects with non-persistently elevated galectin-3 levels. In age-adjusted and sex-adjusted analyses, persistently elevated galectin-3 levels were still associated with an increased risk for new-onset HF and CV mortality (table 2, see supplementary table S5 ). After multivariable adjustment for all baseline characteristics, serial elevated galectin-3 levels remained an independent predictor for new-onset HF, while the predictive value for CV mortality was lost. The independent association of persistently elevated galectin-3 with new-onset HF was primarily attributed to new-onset HFrEF while HFpEF was not significantly predicted, although there was no statistically significant interaction (see supplementary table S6 ; six subjects had an EF between 40% and 50% and were excluded from this subanalysis).
A secondary analysis showing the multivariable analysis of categorical change over time confirmed that subjects in the 'high-high' group impose an increased risk for new-onset HF, while the risk for all-cause mortality was also significantly increased after multivariable adjustment in this analysis (table 3) , while in a tertiary multivariable com- peting-risks regression analysis of absolute change of galectin-3, which was adjusted for baseline galectin-3 levels, the largest increases in galectin-3 were only associated with all-cause mortality (see supplementary table S7 ).
Predictive value of serial measurements compared with single measurement
To assess the predictive value of serial measurements over single measurements for prediction of end points, Harrell's C index was calculated (table 4) . This index was assessed for a single measurement at baseline, a single measurement at follow-up and as a serial measurement at baseline and follow-up. In a direct comparison, serial measurement of galectin-3 had the greatest prognostic accuracy for CV death, new-onset HF, new-onset AF and CV event, but not for all-cause mortality. The addition of changes in galectin-3 to clinical factors resulted in improved classification when assessed by the categoryfree NRI (see supplementary table S8 ). Changes in IDI were small. So, addition of serial galectin-3 is associated with significant increase in NRI and c-statistic for new-onset HF and mortality; however, the clinical impact of these findings is likely limited. 
disCussion
We demonstrate in a large cohort of the general population that persistently elevated galectin-3 levels predict new-onset HF more accurately than a single measurement. In a comparison of persistently elevated versus non-persistently elevated galectin-3 levels, all end points were univariably associated with serial galectin-3 levels, and this association was still present for new-onset HF after full adjustment, although lost for other end points. In a secondary analysis, using low-high categories for a defined cut point, high galectin-3 levels over time were independently associated with new-onset HF and all-cause mortality. Finally, as a third strategy, we studied the association of absolute changes in galectin-3 over time with outcome. Using this strategy of analysis, we observed that, after correction for baseline galectin-3 level, larger absolute increases in galectin-3 levels over time were not independently associated with a higher risk for future CV disease. Subjects with the highest absolute increase in galectin-3 had low galectin-3 levels (10.4 ng/mL) at baseline, which might explain the overall limited risk. Apparently, in the general population, persistent elevated levels of galectin-3 portend stronger risk than increasing galectin-3. In our study, persistently elevated galectin-3 levels over time were compared with non-persistently elevated galectin-3 levels. We selected patients with galectin-3 in the highest quartiles, representing 'elevated' values, which clearly impose the highest risk. This approach was chosen, instead of using a distinct cut-off; each cohort will have its own distinct galectin-3 levels, while a fourth quartile will be applicable to every cohort. As a secondary analysis, we studied change over time using a defined cut point, categorising patients from 'high' to 'low' galectin-3 levels to assess the prognostic value of increasing and decreasing galectin-3 levels across a defined cut point. Furthermore, to assess the importance of the magnitude of increase in galectin-3, we studied absolute changes of galectin-3.
Collectively, serial galectin-3 levels show borderline predictive value for (all-cause and CV) mortality in the general population: some of our analyses suggested a predictive value for all-cause and CV mortality, but these observations were more consistent for all-cause mortality, compared with CV mortality. The multivariable analysis reaffirmed that sex and especially age are important confounders of galectin-3, as was shown previously. 23 Altogether these results indicate that serial galectin-3 levels are particularly useful to predict new-onset HF and possibly mortality, but is of no use to predict newonset AF and CV events in the general population, as was already suggested by single measurements of galectin-3.
24
Prediction of CV disease in the general population remains a challenge, although recent previous research has identified several predictors of new-onset HF. 20 ,25 Baseline biomarkers including age, NT-proBNP, the presence of diabetes mellitus and a history of valvular disease have been shown to predict overall new-onset HF. 25 Whether repeated measurements of prognostic predictors are useful in prediction of outcome in CV disease remains topic of discussion. Biomarkers might reflect underlying changes in pathophysiology and therefore serial measurements might give additional information about the current status of disease. For instance, a substudy of the Val-HeFT trial (Valsartan Heart Failure Trial) showed that serial determinations of NT-proBNP might be a superior strategy for risk stratification of chronic and stable patients with HF. 26 However, each biomarker has its distinct variability over time and can be more or less sensitive to changes in the present disease status.
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Galectin-3 is a biomarker that has shown to be rather stable over time and is not affected by volume loading status. 27 Interestingly, data from four independent cohorts of prevalent HF have strongly suggested that serial measurements show prognostic value in patients with disease. 17 ,28 ,29 Also in ostensibly healthy subjects, single measurements of galectin-3 have shown to be predictive for outcome. [14] [15] [16] In this present study, we now extend these findings by showing that serial galectin-3 measurements in the general population are associated with adverse outcome. Previous studies have already suggested a role for serial galectin-3 measurements to guide therapy, because of its low biological variation. 30 Further, it is well known that fibrosis in cardiac remodelling is a slow phenomenon. 8 Our results can be seen in line with this notion. A short-term increase in galectin-3, therefore, measured by a single measurement, may not be sufficient to induce profound differences. However, long-lasting elevated levels of galectin-3, obtained by serial measurements, may detect subclinical CV disease. Collectively, our results show that persistently elevated galectin-3 is an independent predictor of new-onset HF in the general population. Taken into account these results, serial sampling of galectin-3 can help the clinician to identify apparently healthy subjects who are at risk for development of HF at an early stage. Whether these subjects are amenable to specific pharmacotherapy should be tested. Finally, subjects with lower galectin-3 levels over time can be regarded to be at low risk for development of HF.
study limitations
By design, the PREVEND trial overselected subjects with microalbuminuria. Therefore, we applied a statistical weighting method to correct this so that we were able to extend our conclusions to the general population. Because we study serial measurements, there is a potential risk for survivorship bias, because patients who died between the visits are excluded from the analysis. In our analyses we tried to minimise survivorship bias, by conducting a competing-risks regression. BMI: body mass index; BP: blood pressure; cholesterol: total cholesterol; LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; creatinine: serum creatinine; eGFR: estimated glomerular filtration rate, according to the Modification of Diet in Renal Disease formula; UAE: urinary albumin excretion rate; hs-CRP: high-sensitivity C-reactive protein; NT-proBNP: N-terminal pro-B-type natriuretic peptide. .06
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